GlassScriptPhysician profile
Medi Eslani
NPI 1437614310
$7,161.91
in general payments reported to CMS, 2019-2025
16 companies · $2,922 in 2025
The $2,922 reported for 2025 was more than what 87% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.19 · 2021: $122 · 2022: $618 · 2023: $2,079 · 2024: $1,403 · 2025: $2,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,954 · Travel and Lodging: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,953.59 |
| Travel and Lodging | $450.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,014.69 | 2022-2025 | |
| Alcon Vision LLC | $1,919.01 | 2022-2025 | Clareon, Hydrus Microstent, Argos |
| Sight Sciences, INC. | $665.26 | 2023-2025 | Omni Surgical System |
| Glaukos Corporation | $493.46 | 2023-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $340.30 | 2023-2025 | Via360, Clearpath, Kahook Dual Blade |
| Mallinckrodt Hospital Products INC. | $310.43 | 2024-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $245.72 | 2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $208.32 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $195.57 | 2025 | |
| Bausch & Lomb Americas INC. | $191.56 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $139.45 | 2022-2023 | Tecnis Iol |
| Nova Eye, INC. | $82.74 | 2025 | |
| Thea Pharma INC. | $80.04 | 2024-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $56.28 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $44.11 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $34.77 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Medi Eslani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.